Incyte Corporation (INCY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $24.66B
Last updated: Nov 17, 2026 at 11:06 AM ET
Incyte Corporation (INCY) Financials: Revenue, Profit and Cash Flow
Incyte reported revenue of $5.14B for the fiscal year ended Dec 31, 2025, up 21.2% from the year before. That year, net income was $1.29B with a net margin of 25.0%, operating cash flow was $1.41B and free cash flow was $1.35B. The quarter ended Sep 30, 2026 had revenue of $1.56B and net income of -$784.80M.
Revenue and Margins
The operating margin was 29.5% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $1.11B, a compound annual rate of 18.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $5.14B | +21.2% | 92.8% | 29.5% | 25.0% |
| Dec 2024 | $4.24B | +14.8% | 92.6% | 1.4% | 0.8% |
| Dec 2023 | $3.70B | +8.9% | 93.1% | 16.8% | 16.2% |
| Dec 2022 | $3.39B | +13.7% | 93.9% | 17.1% | 10.0% |
| Dec 2021 | $2.99B | +12.0% | 94.9% | 19.6% | 31.8% |
| Dec 2020 | $2.67B | +23.5% | 95.1% | -9.9% | -11.1% |
| Dec 2019 | $2.16B | +14.7% | 94.7% | 18.6% | 20.7% |
| Dec 2018 | $1.88B | +22.5% | 95.0% | 6.9% | 5.8% |
| Dec 2017 | $1.54B | +38.9% | 94.8% | -15.8% | -20.4% |
| Dec 2016 | $1.11B | N/A | 94.7% | 13.1% | 9.4% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 3854.6% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B | $2.67B | $2.16B | $1.88B | $1.54B | $1.11B |
| Cost of revenue | $372.13M | $312.07M | $254.99M | $207.00M | $150.99M | $131.33M | $114.25M | $94.12M | $79.48M | $58.19M |
| Gross profit | $4.77B | $3.93B | $3.44B | $3.19B | $2.84B | $2.54B | $2.04B | $1.79B | $1.46B | $1.05B |
| Research and development | $2.05B | $2.61B | $1.63B | $1.59B | $1.46B | $2.22B | $1.15B | $1.20B | $1.33B | $581.86M |
| Operating income | $1.51B | $61.37M | $620.52M | $579.44M | $585.78M | -$263.68M | $402.01M | $129.22M | -$243.39M | $145.00M |
| Net income | $1.29B | $32.62M | $597.60M | $340.66M | $948.58M | -$295.70M | $446.91M | $109.49M | -$313.14M | $104.22M |
| EBITDA | $1.63B | $163.42M | $717.12M | N/A | $654.27M | -$188.66M | $508.72M | $215.95M | -$174.06M | $203.42M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.56B | $1.67B | $1.27B | $1.51B | $1.37B | $1.22B | $1.05B | $1.18B | $1.14B | $1.04B | $880.89M | $1.01B |
| Gross profit | $1.45B | $1.57B | $1.17B | $1.39B | $1.27B | $1.14B | $979.71M | $1.09B | $1.05B | $967.13M | $819.93M | $943.59M |
| Operating income | -$708.36M | $697.90M | $301.12M | $335.86M | $443.52M | $530.31M | $205.17M | $301.51M | $146.09M | -$478.13M | $91.90M | $187.27M |
| Net income | -$784.80M | $585.61M | $303.33M | $299.28M | $424.17M | $405.00M | $158.20M | $201.21M | $106.46M | -$444.60M | $169.55M | $201.08M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $41.14M by $3.06B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $6.96B | $5.44B | $6.78B | $5.84B | $4.93B | $3.56B | $3.43B | $2.65B | $2.30B | $1.64B |
| Current assets | $5.02B | $3.24B | $4.65B | $4.09B | $3.12B | $2.36B | $2.48B | $1.83B | $1.50B | $994.18M |
| Cash and equivalents | $3.10B | $1.69B | $3.21B | $2.95B | $2.06B | $1.51B | $1.83B | $1.16B | $899.51M | $652.34M |
| Total liabilities | $1.79B | $2.00B | $1.59B | $1.47B | $1.16B | $949.65M | $828.34M | $719.79M | $671.95M | $1.22B |
| Short-term debt | $41.14M | $39.24M | $38.42M | $36.54M | $37.01M | $38.40M | $52.34M | $31.84M | $34.24M | $19.54M |
| Long-term debt | N/A | $33.54M | $29.16M | $30.08M | $31.63M | N/A | $18.30M | $17.43M | $16.61M | $651.48M |
| Shareholder equity | $5.17B | $3.45B | $5.19B | $4.37B | $3.77B | $2.61B | $2.60B | $1.93B | $1.63B | $419.47M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $7.29B | $7.87B | $7.34B | $6.96B | $6.33B | $5.82B | $5.75B | $5.44B | $5.01B | $4.66B | $7.14B | $6.78B |
| Total liabilities | $1.64B | $1.53B | $1.72B | $1.80B | $1.68B | $1.65B | $2.08B | $2.00B | $1.84B | $1.66B | $1.74B | $1.59B |
| Cash and equivalents | $3.28B | $3.98B | $3.46B | $3.10B | $2.46B | $1.95B | $1.94B | $1.69B | $1.30B | $987.29M | $3.35B | $3.21B |
| Shareholder equity | $5.64B | $6.34B | $5.62B | $5.17B | $4.65B | $4.17B | $3.67B | $3.45B | $3.17B | $3.00B | $5.39B | $5.19B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 95.7% of operating cash flow. Share repurchases came to 1.4% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.41B | $335.34M | $496.49M | $969.94M | $749.49M | -$124.60M | $710.66M | $336.23M | -$92.99M | $304.76M |
| Capital expenditures | $58.87M | $86.26M | $32.49M | $77.83M | $181.01M | $187.38M | $78.06M | $73.48M | $111.02M | $120.28M |
| Free cash flow | $1.35B | $249.07M | $464.00M | $892.11M | $568.48M | -$311.98M | $632.59M | $262.74M | -$204.01M | $184.48M |
| Dividends paid | N/A | N/A | N/A | $26.30M | $29.94M | $22.76M | $16.75M | N/A | $0 | $0 |
| Share repurchases | $19.10M | $2.00B | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$102.61M | $157.52M | -$207.68M | -$78.54M | -$207.70M | -$269.00M | -$87.45M | -$86.42M | -$349.98M | -$232.49M |
| Financing cash flow | $101.04M | -$2.02B | -$20.03M | -$794.00K | $6.18M | $71.71M | $45.71M | $14.66M | $690.21M | $44.62M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$675.32M | $507.66M | $369.35M | $543.30M | $559.39M | $44.74M | $266.07M | $381.22M | $310.87M | -$575.56M | $218.81M | $147.73M |
| Capital expenditures | $15.63M | $12.41M | $10.20M | $21.88M | $14.75M | $19.07M | $3.17M | $17.38M | $5.19M | $54.14M | $9.55M | $2.27M |
| Free cash flow | -$690.95M | $495.25M | $359.15M | $521.42M | $544.64M | $25.67M | $262.90M | $363.83M | $305.68M | -$629.71M | $209.26M | $145.46M |
Frequently Asked Questions About INCY
What is Incyte's annual revenue?
Incyte reported revenue of $5.14B for the fiscal year ended Dec 31, 2025.
How fast is Incyte's revenue growing?
Revenue was up 21.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 14.8%.
Is Incyte profitable?
Yes. Incyte reported net income of $1.29B for the fiscal year ended Dec 31, 2025, with a net margin of 25.0%.
How much free cash flow does INCY generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.41B minus capital expenditures of $58.87M produced free cash flow of $1.35B.
How much debt does Incyte have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $41.14M and cash and equivalents of $3.10B.
INCY pages: Overview, Earnings, Forecast, Financials, Valuation